procarbazine has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 225 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 5.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "The authors present the first case report of a patient with lymphoma who developed disseminated cryptococcal osteomyelitis and meningitis while being treated with the PEP-C (prednisone, etoposide, procarbazine and cyclophosphamide) chemotherapy regimen." | 3.78 | Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. ( Brown, JM; Fan, AC; Felsher, DW; Fischbein, NJ; Howard, W; Hsieh, RW; McClellan, JS; To, CA, 2012) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| " Prognostic factors other than age should be taken into account, particularly when doses and dosing intervals are determined." | 2.68 | Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, procarbazine (COP-BLAM) therapy. ( Niitsu, N, 1997) |
| "However, leukocytopenia was observed in many patients despite combined use of G-CSF, suggesting the dose and administration method of THP should be studied further." | 2.68 | [Usefulness of THP-COPBLM therapy in elderly patients with non-Hodgkin's lymphoma]. ( Nakayama, M; Niitsu, N; Umeda, M, 1997) |
| " These showed that Chinese herbs combined with chemotherapy was a safe and effective method for treating NHL and deserve to be recommended." | 2.68 | [Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy]. ( Guo, XM; Li, JX; Yang, XF, 1997) |
| "The clinical efficacy of COP-BLAM chemotherapy combined with human recombinant granulocyte colony-stimulating factor (G-CSF) was evaluated in 104 previously untreated patients with non-Hodgkin's lymphoma (NHL)." | 2.68 | COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma. ( Niitsu, N; Umeda, M, 1995) |
| "We evaluated the efficacy and adverse effects of biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) therapy combined with granulocyte colony-stimulating factor (G-CSF) for treating non-Hodgkin's lymphoma (NHL)." | 2.68 | Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. ( Niitsu, N; Umeda, M, 1996) |
| "Fourteen had Hodgkin's and four non-Hodgkin's lymphoma." | 2.68 | Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. ( Avivi, I; Ben-Shahar, M; Blumenfeld, Z; Epelbaum, R; Haim, N; Linn, S, 1996) |
| "The response rate and survival in diffuse histiocytic lymphoma have improved since the first study." | 2.64 | Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. ( Coltman, CA; Jones, SE; Luce, JK; McKelvey, EM; Moon, TE, 1977) |
| "Procarbazine hydrochloride is an oral alkylating agent primarily used as a component of chemotherapy regimens for Hodgkin's lymphoma, as well as in regimens for primary central nervous system lymphoma and high-grade gliomas." | 2.46 | Procarbazine-induced hepatotoxicity: case report and review of the literature. ( Becker-Koepke, S; Di Bisceglie, AM; Fesler, MJ; Petruska, PJ, 2010) |
| "Erythema nodosum is the most frequent clinicopathological variant of the panniculitides." | 2.42 | [Erythema nodosum association with malignant lymphoma]. ( Griniūte, R; Pileckyte, M, 2003) |
| "Recent progress in the chemotherapy of malignant lymphoma is described from the viewpoint of survival advantage." | 2.39 | [Recent progress in the chemotherapy of malignant lymphoma]. ( Tobinai, K, 1995) |
| "Chemotherapy of malignant lymphomas has accomplished a significant progress during the two decades." | 2.38 | [Current status of chemotherapy in the treatment of malignant lymphomas]. ( Hayashi, K; Kimura, I; Mizuta, J; Murashima, M; Ohnoshi, T; Tada, A; Tagawa, S; Ueno, K, 1989) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile." | 1.51 | Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019) |
| "Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV." | 1.48 | Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. ( Amores-Fuster, I; Blackwood, L; Finotello, R; Harper, A; Killick, DR; Maddox, TW; Mason, SL; Tanis, JB, 2018) |
| "Seventy-five Hodgkin lymphoma and non-Hodgkin lymphoma patients and a control group of 257 fertile men." | 1.40 | Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. ( Auger, J; Berthaut, I; Brugnon, F; Bujan, L; Daudin, M; Hennebicq, S; Moinard, N; Rives, N; Saias, J; Szerman, E; Walschaerts, M, 2014) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma." | 1.33 | Procarbazine for non-Hodgkin's lymphoma. ( Chaar, BT; Petruska, PJ; Salem, P, 2006) |
| "Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)." | 1.33 | [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "We followed-up 33 patients with non-Hodgkin's lymphoma or with Hodgkin's disease during the years 1987-1997 who were referred for semen cryopreservation." | 1.31 | Follow-up of sperm concentration and motility in patients with lymphoma. ( Botchan, A; Hauser, R; Paz, G; Tal, R; Yavetz, H; Yogev, L, 2000) |
| "Patients treated for Hodgkin's disease and non-Hodgkin lymphomas were followed for 5 years after start of therapy." | 1.30 | Five-year follow-up of saliva in patients treated for lymphomas. ( Keinànen, S; Laine, P; Lindqvist, C; Meurman, JH; Pyrhönen, S; Teerenhovi, L, 1997) |
| "More than 50% of patients with non Hodgkin's lymphomas (NHL) are long-term survivors." | 1.29 | [Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993]. ( Auger, J; Bendahmane, B; Decaudin, D; Koscielny, S; Munck, JN; Naccache, P, 1996) |
| "The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event." | 1.29 | Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. ( Brody, J; Goh, JC; Kaplan, MH; Koduru, P; Lichtman, SM; Susin, M, 1993) |
| "The frequency of chromosome aberrations in the peripheral blood of patients successfully treated for Hodgkin's disease (HD) and non-Hodgkin's lymphoma is compared with that seen in age-matched haematologically normal subjects." | 1.28 | Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma. ( Clark, RE; Jacobs, A; Jones, BM; White, AD, 1992) |
| "5 micrograms/kg/day, sc), which significantly shortened the duration of neutropenia and decreased the number of days with episodes of fever when compared with those not given rhG-CSF, consequently facilitating the treatment without prolonging the dosing intervals." | 1.28 | [The COP-BLAM III therapy of non-Hodgkin's lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| " The optimal dosing for MV26PD remains to be determined." | 1.27 | Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. ( Anderson, J; Bloomfield, CD; Cooper, MR; Ginsberg, SJ; Gottlieb, AJ; Hurd, DD; Lachant, NA, 1988) |
| "However, brain metastases were not immediate death-causing factors." | 1.27 | [Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas]. ( Kruglova, GV; Setdikov, RA, 1986) |
| "Seventeen patients with non-Hodgkin's lymphoma (NHL) and 2 patients with Hodgkin's disease (HD) were treated by combination chemotherapy (COPP or CHOP), and then received 300 X 10(4) U of alpha-IFN daily for 14 days." | 1.27 | [A preliminary study of chemo-interferon therapy in malignant lymphoma]. ( Fukutani, H; Takeyama, H; Watanabe, E; Yano, K, 1987) |
| "15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC." | 1.26 | Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations. ( Donner, L; Klener, P, 1977) |
| "A 77-year-old woman with reticulum cell sarcoma in apparent remission presented with neovascular glaucoma." | 1.26 | Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. ( Dallow, RI; Sullivan, SF, 1977) |
| "For patients with lymphosarcoma the average duration of complete remission was 26." | 1.26 | [Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)]. ( Hiller, E; Schmülling, RM; Tigges, FJ; Waller, HD; Wilms, K, 1977) |
| "The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%)." | 1.25 | Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. ( Amiel, JL; Hayat, M; Mathé, G; Pouillart, P; Schwarzenberg, L; Tubiana, M, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a histologically proven complete remission after 6 months of treatment without maintenance have remained disease-free whereas those with nodular poorly differentiated lymphocytic and diffuse well-differentiated lymphocytic lymphomas have demonstrated a pattern of continuous late recurrence." | 1.25 | Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. ( Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RC, 1975) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 1.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a complete remission after 6 months of treatment without maintenance have remained disease-free, whereas those with nodular poorly differentiated lymphocytic and diffuse well differentiated lymphocytic lymphomata demonstrate a pattern of continuous late recurrence." | 1.25 | Results of combination chemotherapy of non-Hodgkin's lymphoma. ( Berard, C; Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RD, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 85 (37.78) | 18.7374 |
| 1990's | 97 (43.11) | 18.2507 |
| 2000's | 27 (12.00) | 29.6817 |
| 2010's | 12 (5.33) | 24.3611 |
| 2020's | 4 (1.78) | 2.80 |
| Authors | Studies |
|---|---|
| Nagane, M | 1 |
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Wirdah, A | 1 |
| Djamaludin, N | 1 |
| Syahrir, M | 1 |
| Andayani, YD | 1 |
| Andriani, M | 1 |
| Diansari, Y | 1 |
| Zimmerman, K | 1 |
| Walsh, KA | 1 |
| Ferrari, JT | 1 |
| Keuler, NS | 1 |
| Atherton, MJ | 1 |
| Lenz, JA | 1 |
| Tanis, JB | 1 |
| Mason, SL | 1 |
| Maddox, TW | 1 |
| Blackwood, L | 1 |
| Killick, DR | 1 |
| Amores-Fuster, I | 1 |
| Harper, A | 1 |
| Finotello, R | 1 |
| Faivre, G | 2 |
| Butler, MJ | 1 |
| Le, I | 1 |
| Brenner, A | 1 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 4 |
| Skoetz, N | 1 |
| Bujan, L | 1 |
| Walschaerts, M | 1 |
| Brugnon, F | 1 |
| Daudin, M | 1 |
| Berthaut, I | 1 |
| Auger, J | 2 |
| Saias, J | 1 |
| Szerman, E | 1 |
| Moinard, N | 1 |
| Rives, N | 1 |
| Hennebicq, S | 1 |
| Omuro, A | 2 |
| Correa, DD | 1 |
| DeAngelis, LM | 4 |
| Moskowitz, CH | 1 |
| Matasar, MJ | 1 |
| Kaley, TJ | 1 |
| Gavrilovic, IT | 1 |
| Nolan, C | 1 |
| Pentsova, E | 1 |
| Grommes, CC | 1 |
| Panageas, KS | 1 |
| Baser, RE | 1 |
| Abrey, LE | 3 |
| Sauter, CS | 1 |
| Fukushima, R | 1 |
| Kobayashi, Y | 1 |
| Fukuhara, S | 2 |
| Miyamoto, K | 1 |
| Munakata, W | 1 |
| Maruyama, D | 1 |
| Kim, SW | 1 |
| Watanabe, T | 1 |
| Taniguchi, H | 1 |
| Maeshima, A | 1 |
| Tobinai, K | 4 |
| Illerhaus, G | 2 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 2 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 2 |
| Mwanda, WO | 1 |
| Orem, J | 1 |
| Fu, P | 1 |
| Banura, C | 1 |
| Kakembo, J | 1 |
| Onyango, CA | 1 |
| Ness, A | 1 |
| Reynolds, S | 1 |
| Johnson, JL | 1 |
| Subbiah, V | 1 |
| Bako, J | 1 |
| Wabinga, H | 1 |
| Abdallah, FK | 1 |
| Meyerson, HJ | 1 |
| Whalen, CC | 1 |
| Lederman, MM | 1 |
| Black, J | 1 |
| Ayers, LW | 1 |
| Katongole-Mbidde, E | 1 |
| Remick, SC | 2 |
| Fesler, MJ | 1 |
| Becker-Koepke, S | 1 |
| Di Bisceglie, AM | 1 |
| Petruska, PJ | 2 |
| Cronin, PA | 1 |
| Myers, E | 1 |
| Redmond, HP | 1 |
| O'Reilly, S | 1 |
| Kirwan, WO | 1 |
| Scholz, M | 1 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 2 |
| Fritsch, K | 1 |
| Kasenda, B | 1 |
| Hader, C | 1 |
| Nikkhah, G | 1 |
| Prinz, M | 1 |
| Haug, V | 1 |
| Haug, S | 1 |
| Welch, MR | 1 |
| To, CA | 1 |
| Hsieh, RW | 1 |
| McClellan, JS | 1 |
| Howard, W | 1 |
| Fischbein, NJ | 1 |
| Brown, JM | 1 |
| Felsher, DW | 1 |
| Fan, AC | 1 |
| Theodossiou, C | 1 |
| Schwarzenberger, P | 1 |
| Tsimberidou, AM | 1 |
| McLaughlin, P | 2 |
| Younes, A | 2 |
| Rodriguez, MA | 2 |
| Hagemeister, FB | 2 |
| Sarris, A | 2 |
| Romaguera, J | 2 |
| Hess, M | 1 |
| Smith, TL | 1 |
| Yang, Y | 1 |
| Ayala, A | 1 |
| Preti, A | 1 |
| Lee, MS | 2 |
| Cabanillas, F | 3 |
| Pileckyte, M | 1 |
| Griniūte, R | 1 |
| TODD, ID | 1 |
| BEGEMANN, H | 1 |
| BLUM, KU | 1 |
| FELLMER, KE | 1 |
| FOELSCH, E | 1 |
| GERHARTZ, H | 4 |
| GRUNZE, H | 1 |
| HAUSMANN, K | 1 |
| HENNES, R | 1 |
| JUENGLING, W | 1 |
| KLEIBEL, F | 1 |
| KOERTGE, P | 1 |
| MARING, H | 1 |
| MARTIN, H | 1 |
| OBRECHT, P | 1 |
| OSTEN, W | 1 |
| PABST, HW | 1 |
| POLIWODA, H | 2 |
| SCHUBERT, JC | 1 |
| SEIDL, S | 1 |
| SPECHTER, HJ | 1 |
| STRICKSTROCK, KH | 1 |
| WITTE, S | 1 |
| DREWS, J | 1 |
| Ogawa, M | 1 |
| Mandigers, CM | 1 |
| Verdonck, LF | 1 |
| Meijerink, JP | 1 |
| Dekker, AW | 1 |
| Schattenberg, AV | 1 |
| Raemaekers, JM | 2 |
| Hehn, ST | 1 |
| Miller, TP | 2 |
| Lai, R | 1 |
| Rosenblum, MK | 1 |
| Yamamoto, R | 1 |
| Hashiguchi, K | 1 |
| Iwai, A | 1 |
| Satoh, S | 1 |
| Hanaoka, N | 1 |
| Okudaira, K | 1 |
| Inoue, T | 1 |
| Miyazaki, J | 1 |
| Matsuzaki, K | 1 |
| Tsuzuki, Y | 1 |
| Kawaguchi, A | 1 |
| Nagao, S | 1 |
| Itoh, K | 1 |
| Miura, S | 1 |
| Hatano, B | 1 |
| Wessels, G | 1 |
| Bernard Hesseling, P | 1 |
| Herrlinger, U | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Moser, EC | 1 |
| Noordijk, EM | 3 |
| Carde, P | 2 |
| Tirelli, U | 3 |
| Baars, JW | 1 |
| Thomas, J | 3 |
| Bron, D | 2 |
| Meerwaldt, JH | 3 |
| van Glabbeke, M | 2 |
| Kluin-Nelemans, HC | 1 |
| Di Renzo, N | 1 |
| Brugiatelli, M | 1 |
| Montanini, A | 1 |
| Vigliotti, ML | 1 |
| Cervetti, G | 1 |
| Liberati, AM | 1 |
| Luminari, S | 1 |
| Spedini, P | 1 |
| Giglio, G | 1 |
| Federico, M | 1 |
| Mizoroki, F | 1 |
| Hirose, Y | 1 |
| Sano, M | 1 |
| Fukuda, H | 1 |
| Nakata, M | 1 |
| Taniwaki, M | 1 |
| Kawano, F | 1 |
| Uozumi, K | 1 |
| Sawada, K | 1 |
| Nasu, K | 1 |
| Ohno, Y | 1 |
| Toki, H | 1 |
| Togawa, A | 1 |
| Kikuchi, M | 1 |
| Hotta, T | 1 |
| Shimoyama, M | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Chaar, BT | 1 |
| Salem, P | 1 |
| Smith, S | 1 |
| Portlock, CS | 2 |
| Klastersky, J | 1 |
| Jacquillat, C | 1 |
| Khayat, D | 1 |
| Desprez-Curely, JP | 1 |
| Weil, M | 1 |
| Brocheriou, C | 1 |
| Auclerc, G | 1 |
| Chamseddine, N | 1 |
| Bernard, J | 1 |
| Coyne, J | 1 |
| Dervan, P | 1 |
| Kueh, YK | 1 |
| Tan, YO | 1 |
| Sng, I | 1 |
| Rauff, A | 1 |
| Engelhard, M | 8 |
| Brittinger, G | 8 |
| Fuchs, R | 2 |
| Geiseler, B | 1 |
| Gerhartz, D | 1 |
| Haunauske, AR | 1 |
| Hartlapp, HJ | 1 |
| Huhn, D | 6 |
| Swan, F | 1 |
| Pate, O | 1 |
| Somers, R | 3 |
| Keuning, JJ | 1 |
| Delmer, A | 1 |
| de Bock, R | 1 |
| De Wolf-Peeters, C | 2 |
| Keunig, JJ | 1 |
| Sertoli, MR | 1 |
| Santini, G | 2 |
| Chisesi, T | 2 |
| Congiu, AM | 1 |
| Rubagotti, A | 1 |
| Contu, A | 2 |
| Salvagno, L | 2 |
| Coser, P | 2 |
| Porcellini, A | 2 |
| Vespignani, M | 1 |
| Tanabe, J | 1 |
| Kanamori, H | 1 |
| Matsuzaki, M | 1 |
| Motomura, S | 1 |
| Mohri, H | 1 |
| Okubo, T | 1 |
| Maruta, A | 1 |
| Kodama, F | 1 |
| Vose, JM | 3 |
| Anderson, JR | 2 |
| Bierman, PJ | 3 |
| Bast, M | 2 |
| Weisenburger, D | 1 |
| Chan, WC | 1 |
| Bishop, MR | 1 |
| Armitage, JO | 5 |
| Niitsu, N | 18 |
| Umeda, M | 19 |
| Longo, DL | 4 |
| Duffey, PL | 2 |
| Jaffe, ES | 3 |
| Raffeld, M | 1 |
| Hubbard, SM | 3 |
| Fisher, RI | 6 |
| Wittes, RE | 1 |
| DeVita, VT | 12 |
| Young, RC | 9 |
| Shpilberg, O | 1 |
| Shiff, J | 1 |
| Chetrit, A | 1 |
| Ramot, B | 1 |
| Ben-Bassat, I | 1 |
| Siegert, W | 4 |
| Nerl, C | 1 |
| Tiemann, M | 1 |
| Parwaresch, R | 1 |
| Heinz, R | 4 |
| Gerhartz, HH | 4 |
| Schlimok, G | 2 |
| Thiel, E | 5 |
| Huber, C | 1 |
| Emmerich, B | 1 |
| Schadek, C | 1 |
| Brandmaier, R | 1 |
| Stern, AC | 1 |
| Avilés, A | 3 |
| Díaz-Maqueo, JC | 2 |
| Talavera, A | 2 |
| Nambo, MJ | 1 |
| García, EL | 2 |
| Dreger, P | 1 |
| Klöss, M | 1 |
| Petersen, B | 1 |
| Haferlach, T | 1 |
| Löffler, H | 2 |
| Schmitz, N | 1 |
| Teodorovic, I | 2 |
| Pittaluga, S | 2 |
| Kluin-Nelemans, JC | 1 |
| Hagenbeek, A | 2 |
| Bijnens, L | 2 |
| Peeters, CD | 1 |
| Lichtman, SM | 1 |
| Brody, J | 1 |
| Kaplan, MH | 1 |
| Susin, M | 1 |
| Koduru, P | 1 |
| Goh, JC | 1 |
| Hara, A | 6 |
| Shirai, T | 8 |
| Meusers, P | 4 |
| Wilmanns, W | 2 |
| Mueller, P | 1 |
| Musch, R | 1 |
| Kaneko, H | 3 |
| Vose, J | 1 |
| Kessinger, A | 1 |
| Jurcic, JG | 1 |
| Koll, B | 1 |
| Brown, AE | 1 |
| Crown, JP | 1 |
| Yahalom, J | 2 |
| Gulati, SC | 1 |
| Baxter, JD | 1 |
| DiNubile, MJ | 1 |
| Bokemeyer, C | 1 |
| Schmoll, HJ | 1 |
| van Rhee, J | 1 |
| Kuczyk, M | 1 |
| Schuppert, F | 1 |
| Kyrtopoulos, SA | 1 |
| Souliotis, VL | 1 |
| Valavanis, C | 1 |
| Boussiotis, VA | 1 |
| Pangalis, GA | 1 |
| McSharry, JJ | 1 |
| Wolf, BC | 1 |
| Blanchard, CG | 1 |
| Eastman, AY | 1 |
| Wagner, H | 1 |
| Portuese, E | 1 |
| Wighton, T | 1 |
| Powell, D | 1 |
| Pearce, T | 1 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Zdziarska, B | 1 |
| Nowacki, P | 1 |
| Millo, B | 1 |
| Kaźmierczak, M | 1 |
| Komarnicki, M | 1 |
| Kroll, R | 1 |
| Haim, N | 3 |
| Leviov, M | 1 |
| Ben-Arieh, Y | 1 |
| Epelbaum, R | 2 |
| Freidin, N | 1 |
| Reshef, R | 1 |
| Ben-Shahar, M | 3 |
| Naccache, P | 1 |
| Decaudin, D | 1 |
| Koscielny, S | 1 |
| Bendahmane, B | 1 |
| Munck, JN | 1 |
| Shchepotin, IB | 1 |
| Evans, SR | 1 |
| Shabahang, M | 1 |
| Chorny, V | 1 |
| Buras, RR | 1 |
| Korobko, V | 1 |
| Zadorozhny, A | 1 |
| Nauta, RJ | 1 |
| Gaynor, ER | 2 |
| Izumi, T | 1 |
| Ohtsuki, T | 1 |
| Ohya, K | 1 |
| Ogawa, Y | 1 |
| Yoshida, M | 1 |
| Muroi, K | 2 |
| Imagawa, S | 1 |
| Hatake, K | 1 |
| Kuriki, K | 1 |
| Saito, K | 1 |
| Miura, Y | 1 |
| Burney, IA | 1 |
| Malik, IA | 1 |
| Blumenfeld, Z | 2 |
| Avivi, I | 1 |
| Linn, S | 1 |
| Nakayama, M | 2 |
| Brockmeyer, NH | 1 |
| Pohl, G | 1 |
| Mertins, L | 1 |
| Meurman, JH | 2 |
| Laine, P | 2 |
| Keinànen, S | 1 |
| Pyrhönen, S | 2 |
| Teerenhovi, L | 2 |
| Lindqvist, C | 2 |
| Barai, U | 1 |
| Teoh, N | 1 |
| Kamieńska, E | 1 |
| Corti, C | 1 |
| Theodore, C | 1 |
| Bayle, C | 1 |
| Rougier, P | 1 |
| Nasr, F | 1 |
| Cosset, JM | 1 |
| Girinsky, T | 1 |
| Hayat, M | 2 |
| Ribrag, V | 1 |
| Mac Manus, MP | 1 |
| Hoppe, RT | 1 |
| Ritter, M | 1 |
| Shen-Orr, Z | 1 |
| Shariki, K | 1 |
| Sonnen, R | 1 |
| Kuse, R | 1 |
| Bairey, O | 1 |
| Gabbay, U | 1 |
| Blickstein, D | 1 |
| Stark, P | 1 |
| Prokocimer, M | 1 |
| Epstein, O | 1 |
| Shaklai, M | 1 |
| Lahav, J | 1 |
| Palmieri, G | 1 |
| Morabito, A | 1 |
| Rea, A | 1 |
| Biondi, E | 1 |
| Lauria, R | 1 |
| Matano, E | 1 |
| Pagliarulo, C | 1 |
| Montesarchio, V | 1 |
| Tagliaferri, P | 1 |
| Bianco, AR | 1 |
| Korfel, A | 1 |
| Yamazaki, J | 1 |
| Guo, XM | 1 |
| Li, JX | 1 |
| Yang, XF | 1 |
| Kuraishi, Y | 1 |
| Usui, N | 1 |
| Dobashi, N | 1 |
| Kamath, SS | 1 |
| Marcus, RB | 1 |
| Lynch, JW | 1 |
| Mendenhall, NP | 1 |
| Merlo, EM | 1 |
| Maiolo, A | 1 |
| Brocchieri, A | 1 |
| Tua, A | 1 |
| Grignani, G | 1 |
| Dubey, SP | 1 |
| Sengupta, SK | 1 |
| Kaleh, LK | 1 |
| Morewaya, JT | 1 |
| Keyaki, A | 1 |
| Nabeshima, S | 1 |
| Waga, S | 1 |
| Dana, BW | 1 |
| LeBlanc, M | 1 |
| Kjeldsberg, C | 1 |
| Forman, JD | 1 |
| Unger, JM | 1 |
| Balcerzak, SP | 1 |
| Roy, V | 1 |
| Miller, T | 1 |
| Yong, W | 1 |
| Zhang, YT | 1 |
| Wei, Y | 1 |
| Tal, R | 1 |
| Botchan, A | 1 |
| Hauser, R | 1 |
| Yogev, L | 1 |
| Paz, G | 1 |
| Yavetz, H | 1 |
| Iijima, K | 1 |
| Chizuka, A | 1 |
| Trenhaile, TR | 1 |
| Killackey, MA | 1 |
| Kirchner, EM | 1 |
| Ebsen, M | 1 |
| Kirchner, J | 1 |
| Theegarten, D | 1 |
| Voigtmann, R | 1 |
| Neri, N | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 1 |
| Amiel, JL | 1 |
| Mathé, G | 1 |
| Tubiana, M | 1 |
| Klener, P | 2 |
| Donner, L | 2 |
| Anderson, T | 1 |
| Bender, RA | 1 |
| Chabner, BA | 6 |
| Berard, CW | 2 |
| Norton, L | 1 |
| Coltman, CA | 1 |
| Luce, JK | 1 |
| McKelvey, EM | 1 |
| Jones, SE | 1 |
| Moon, TE | 1 |
| Bennett, JM | 1 |
| Lenhard, RE | 1 |
| Ezdinli, E | 1 |
| Johnson, GJ | 2 |
| Carbone, PP | 4 |
| Pocock, SJ | 1 |
| Poster, DS | 1 |
| Sullivan, SF | 1 |
| Dallow, RI | 1 |
| Goldberg, J | 1 |
| Davey, FR | 1 |
| Gottlieb, AJ | 2 |
| Johnson, RE | 1 |
| Canellos, GP | 7 |
| Brereton, HD | 1 |
| Tigges, FJ | 1 |
| Schmülling, RM | 1 |
| Hiller, E | 1 |
| Waller, HD | 1 |
| Wilms, K | 1 |
| Rubio-Félix, D | 1 |
| Maicas, M | 1 |
| Rubio-Vitaller, A | 1 |
| Gil, JL | 1 |
| Giralt, M | 1 |
| Raichs, A | 1 |
| Karpf, PM | 1 |
| Mang, W | 1 |
| Harrison, DT | 1 |
| Neiman, PE | 1 |
| Sullivan, K | 1 |
| Hafermann, M | 1 |
| Rudolph, RH | 1 |
| Einstein, AB | 1 |
| Klein, HO | 1 |
| Yoshikawa, S | 1 |
| Morishima, Y | 1 |
| Benjamin, RS | 1 |
| Wiernik, PH | 1 |
| O'Connell, MJ | 2 |
| Chang, P | 1 |
| Sutherland, JC | 1 |
| Schein, PS | 3 |
| Morgenfeld, MC | 1 |
| Pavlovsky, A | 1 |
| Suarez, A | 1 |
| Somoza, N | 1 |
| Pavlovsky, S | 1 |
| Palau, M | 1 |
| Barros, CA | 1 |
| Young, RD | 1 |
| Berard, C | 2 |
| Bergsagel, DE | 1 |
| Brown, TC | 1 |
| Reid, J | 1 |
| Tenovuo, J | 1 |
| Murtomaa, H | 1 |
| Dodwell, DJ | 1 |
| de Campos, ES | 1 |
| Radford, JA | 1 |
| Chamberlain, MC | 2 |
| Levin, VA | 2 |
| Zeymer, U | 1 |
| Hirschmann, WD | 1 |
| Neuhaus, KL | 1 |
| White, AD | 1 |
| Jones, BM | 1 |
| Clark, RE | 1 |
| Jacobs, A | 1 |
| Alter, R | 1 |
| Joshi, SS | 1 |
| Verdirame, JD | 1 |
| Weisenburger, DD | 5 |
| Conlan, MG | 1 |
| Arai, N | 5 |
| Wesley, MN | 1 |
| Ihde, DC | 2 |
| Gilliom, M | 1 |
| Cossman, J | 2 |
| Guzmán, R | 1 |
| Brack, N | 1 |
| Dornoff, W | 1 |
| Enne, W | 2 |
| Gassmann, W | 1 |
| Hallek, M | 1 |
| Heise, J | 1 |
| Zurborn, KH | 1 |
| Gram, J | 1 |
| Glander, K | 1 |
| Delbrück, K | 1 |
| Pelzer, H | 1 |
| Bruhn, HD | 1 |
| Capnist, G | 1 |
| Rizzoli, V | 1 |
| Sertoli, M | 1 |
| Rancan, L | 1 |
| Bashir, RM | 1 |
| Gutiérrez, J | 1 |
| Osorio, G | 1 |
| García, H | 1 |
| Vacarezza, R | 1 |
| Cao, C | 1 |
| Carrión, JR | 1 |
| Delgado, JR | 1 |
| Dominguez, S | 1 |
| Flores, E | 1 |
| Garcia, P | 1 |
| Jaen, J | 1 |
| Santos, JA | 1 |
| el-Ghamrawy, KA | 1 |
| Zawam, HZ | 1 |
| Abdel-Azim, H | 1 |
| Haggag, M | 1 |
| Strauss, B | 2 |
| Sagher, D | 2 |
| Karrison, T | 2 |
| Schwartz, J | 1 |
| Larson, R | 2 |
| Williams, S | 1 |
| Debranin, CO | 1 |
| Chao, NJ | 1 |
| Rosenberg, SA | 1 |
| Horning, SJ | 1 |
| Watkin, SW | 1 |
| Green, JA | 1 |
| Bagella, MP | 1 |
| Fadda, G | 1 |
| Cherchi, PL | 1 |
| Gisselbrecht, C | 2 |
| Lepage, E | 2 |
| Sebban, C | 1 |
| Coiffier, B | 1 |
| Coleman, M | 2 |
| Gerstein, G | 1 |
| Topilow, A | 1 |
| Lebowicz, J | 1 |
| Berhardt, B | 1 |
| Chiarieri, D | 1 |
| Silver, RT | 2 |
| Pasmantier, MW | 2 |
| Harrington, DP | 1 |
| Earle, JD | 1 |
| Glick, JH | 1 |
| Creech, RH | 1 |
| Neiman, RS | 1 |
| Mann, RB | 1 |
| Silverstein, MN | 1 |
| Cunningham, D | 1 |
| Hepplestone, A | 1 |
| Gilchrist, NL | 1 |
| Dagg, JH | 1 |
| Evans, IL | 1 |
| Soukop, M | 1 |
| Lawrence, TS | 1 |
| Urba, WJ | 1 |
| Steinberg, SM | 1 |
| Sundeen, JT | 1 |
| Glatstein, E | 2 |
| Dörken, B | 1 |
| Engert, W | 1 |
| Hagen-Aukamp, CH | 1 |
| Neubauer, A | 1 |
| Stacher, A | 3 |
| Schwartz, JL | 1 |
| Meier, P | 1 |
| Brice, P | 1 |
| Trédaniel, J | 1 |
| Gerota, I | 1 |
| Gaynor, M | 1 |
| McDermott, D | 1 |
| Adler, K | 1 |
| Beshevkin, M | 1 |
| Reisman, AM | 1 |
| Zagonel, V | 1 |
| Volpe, R | 1 |
| Trovò, MG | 1 |
| Carbone, A | 1 |
| Sorensen, S | 1 |
| Hutchins, M | 1 |
| Moravec, DF | 1 |
| Howe, D | 1 |
| Dowling, MD | 1 |
| Mailliard, J | 1 |
| Nowrousian, MR | 1 |
| Meier, CR | 1 |
| Schoetensack, B | 1 |
| Anders, C | 1 |
| Höffken, K | 1 |
| Osieka, R | 1 |
| Schmidt, CG | 1 |
| Ohnoshi, T | 1 |
| Hayashi, K | 1 |
| Ueno, K | 1 |
| Tada, A | 1 |
| Murashima, M | 1 |
| Mizuta, J | 1 |
| Tagawa, S | 1 |
| Kimura, I | 1 |
| Kindzel'skiĭ, LP | 1 |
| Gubareva, AA | 1 |
| Shirakawa, S | 1 |
| Shimizu, K | 1 |
| Shinkai, K | 2 |
| Kojima, H | 2 |
| Maruyama, F | 2 |
| Sobue, R | 2 |
| Ito, N | 2 |
| Imura, H | 2 |
| Matsui, T | 1 |
| Ino, T | 2 |
| Brown, T | 1 |
| Dawson, AA | 1 |
| Bennett, B | 1 |
| Moore, NR | 1 |
| Lachant, NA | 1 |
| Anderson, J | 1 |
| Ginsberg, SJ | 1 |
| Cooper, MR | 1 |
| Hurd, DD | 1 |
| Bloomfield, CD | 1 |
| Wagstaff, J | 1 |
| Todd, I | 1 |
| Deakin, D | 1 |
| Wilkinson, P | 1 |
| Scarffe, JH | 1 |
| Harris, M | 1 |
| Jones, M | 1 |
| Crowther, D | 1 |
| España, P | 1 |
| Bonilla, F | 1 |
| Yebra, M | 1 |
| Diego, J | 1 |
| Alvarez de Mon, M | 1 |
| Marazuela, M | 1 |
| Durántez, A | 1 |
| Stuart, NS | 1 |
| Blackledge, GR | 1 |
| Child, JA | 1 |
| Fletcher, J | 1 |
| Perren, TJ | 1 |
| O'Brien, CJ | 1 |
| Jones, EL | 1 |
| Ellis, IO | 1 |
| Kavanagh, JA | 1 |
| Kelly, KA | 1 |
| Furukawa, Y | 1 |
| Takagi, S | 1 |
| Tsuboyama, A | 1 |
| Tsunoda, S | 1 |
| Akashi, M | 1 |
| Komatsu, N | 1 |
| Takeda, K | 1 |
| Akutsu, M | 1 |
| Ohsaka, A | 1 |
| Abate, G | 1 |
| Comella, P | 1 |
| Di Pietro, N | 1 |
| Ganzina, F | 1 |
| Pergola, M | 1 |
| Silvestro, P | 1 |
| Basso, A | 1 |
| Salvatore, M | 1 |
| Zarrilli, D | 1 |
| Okamoto, M | 1 |
| Takada, T | 1 |
| Morikawa, K | 1 |
| Setdikov, RA | 1 |
| Kruglova, GV | 1 |
| Takeyama, H | 1 |
| Yano, K | 1 |
| Fukutani, H | 1 |
| Watanabe, E | 1 |
| Hanak, H | 1 |
| Stenzel, L | 1 |
| Krug, K | 1 |
| Schingnitz, G | 1 |
| Davis, P | 1 |
| Mims, CH | 1 |
| Costanzi, JJ | 1 |
| Keipert, JA | 1 |
| Nissen, NI | 1 |
| Walbom-Jorgensen, S | 1 |
| Brodskaia, NA | 1 |
| Rubin, P | 1 |
| Gociu, M | 1 |
| Sherins, RJ | 2 |
| De Vita, VT | 1 |
| Schein, PJ | 1 |
| Bagley, CM | 1 |
| Host, H | 1 |
| Abrahamsen, AF | 1 |
| Aungst, CW | 1 |
| Buffet, C | 1 |
| Bonnefond, A | 1 |
| Mignon, M | 1 |
| Hakim, J | 1 |
| Arseneau, JC | 1 |
| Stein, RS | 1 |
| Moran, EM | 1 |
| Desser, RK | 1 |
| Miller, JB | 1 |
| Golomb, HM | 1 |
| Ultmann, JE | 2 |
| Spivack, SD | 1 |
| Dohner, VA | 1 |
| Ward, HP | 1 |
| Standord, RE | 1 |
| Frei, E | 1 |
| McElwain, TJ | 1 |
| Gamble, JF | 1 |
| Fuller, LM | 1 |
| Butler, JJ | 1 |
| Shullenberger, CC | 1 |
| Mukherji, B | 1 |
| Oettgen, HF | 1 |
| Yagoda, A | 1 |
| Krakoff, IH | 1 |
| Kurnick, JE | 1 |
| Robinson, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)[NCT00596154] | Phase 2 | 33 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma[NCT00005780] | Phase 2 | 26 participants (Actual) | Interventional | 2000-06-01 | Completed | ||
| Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University[NCT00902720] | Phase 4 | 25 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being[NCT02749474] | 400 participants (Anticipated) | Observational [Patient Registry] | 2003-07-31 | Recruiting | |||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00005780)
Timeframe: Up to 30 days after last intervention, up to 12.5 months or 1.04 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 26 |
PFS is time from on study date until disease relapse or progression, death, or date of last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: From participants on study date until date of disease relapse or progression, death, or date of last follow-up, assessed up to 245.8 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 23.5 |
OS was determined by the Kaplan-Meier method and is defined as the time from treatment start date until date of death or last follow-up. (NCT00005780)
Timeframe: Time from treatment start date until date of death or date last follow-up, up to 250 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 89.7 |
Participants with an immune response to idiotype vaccine measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: Weeks 12 to 32
| Intervention | percentage of participants (Number) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 30 |
Participants with an immune response against carrier molecule KLH measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months
| Intervention | percentage of participants (Number) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 74 |
PFS is defined as the time from start of treatment until disease relapse or progression, death, or last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion (NCT00005780)
Timeframe: Time from treatment start date until date of disease relapse or progression, death, or date last follow-up, an average of 25 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 25.0 |
Recovery of CD4+ was measured by flow cytometry. Blood samples were collected via apheresis and analyzed by multicolor flow cytometry in peripheral blood mononuclear cells (PBMCs) for cluster of differentiation 4 (CD4). Time to recovery of CD4 T lymphocytes was defined as the time required for CD4 T lymphocytes to increase above the lower limit of normal of the normal laboratory value range of 359 cells/mcL (NCT00005780)
Timeframe: After chemotherapy before vaccination, up to 6 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 3 |
Response was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma. Complete Response (CR) is a complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., Lactate dehydrogenase (LDH) definitely assignable to the lymphoma. Complete Response Unconfirmed (CRu) is as per CR criteria except that if a residual node is > 1.5cm, it must have regressed by > 75% in the sum of the products of the greatest diameters (SPD). Partial Response (PR) is ≥50% decreased in the SPD of 6 largest dominant nodes or nodal masses. Stable Disease (SD) is defined as less than a PR but not progressive disease. Progression is ≥50% increase from nadir in the SPD of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: After 6 cycles of EPOCH-R therapy, an average of 18 weeks
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Complete Response Unconfirmed | Partial Response | Stable Disease | Progression | |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 80.8 | 7.7 | 7.7 | 0 | 3.8 |
Serious and/or non-serious adverse events were assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event. (NCT00005780)
Timeframe: Up to 30 days after last intervention, up to 12.5 months or 1.04 years
| Intervention | percentage of participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction | Anemia | Febrile neutropenia | Leukopenia | Lymphopenia | Neutropenia | Thrombocytopenia | Thrombosis | Infusion related reaction | Serum glutamic oxaloacetic transaminase (SGOT) elevation | Serum glutamic pyruvic transaminase (SGPT) elevation | Infection | Hyperglycemia | Hypomagnesemia | Cerebrovascular ischemia | Motor neuropathy | Sensory neuropathy | Back pain | Dyspnea | Erectile dysfunction | |
| Grade 3 | 3.8 | 69.2 | 42.3 | 0 | 38.5 | 0 | 50 | 15.4 | 3.8 | 3.8 | 3.8 | 15.4 | 3.8 | 3.8 | 0 | 11.5 | 3.8 | 3.8 | 3.8 | 3.8 |
| Grade 4 | 0 | 3.8 | 3.8 | 84.6 | 0 | 88.5 | 7.7 | 0 | 0 | 0 | 0 | 3.8 | 0 | 0 | 3.8 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants with tumor specific T-cell responses during B-cell recovery was assessed in a Clinical Laboratory Improvement Amendments (CLIA) certified lab and were measured by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT). A positive response required the response to be at least twice the negative controls. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Granulocyte macrophage colony-stimulating factor (GM-CSF) | Tumor necrosis factor α (TNFα) | Interferon-gamma (IFN-γ) | |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 87 | 65 | 52 | 74 |
31 reviews available for procarbazine and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Procarbazine-induced hepatotoxicity: case report and review of the literature.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injur | 2010 |
Lipomatosis: an unusual side-effect of cytotoxic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lipomatosis; Lymphoma, Non-Hodgkin; Male; Me | 2010 |
Non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, AID | 2002 |
[Erythema nodosum association with malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Diagnosis, Dif | 2003 |
[Hematologic tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine | 2003 |
What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2004 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradia | 2004 |
Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Transfusion; Child; Combined | 2005 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1984 |
[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyt | 1995 |
[Elderly non-Hodgkin's lymphoma arising in left brachial soft tissue].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Bleomycin; Combined Modality Therapy; Cyc | 1993 |
[Recent progress in the chemotherapy of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 1995 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; C | 1996 |
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Cyclo | 1995 |
Overview of treatment of localized low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; California; Chemotherap | 1997 |
[Chemotherapy for non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1998 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 1992 |
[Massive bilateral non-Hodgkin's lymphoma of the adrenal glands].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1990 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
[The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Dacarbazine; | 1988 |
[Current status of chemotherapy in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1989 |
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma; Lymp | 1972 |
[Natulan (experimental and clinical data on its antitumor effect)].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Bronchial Neoplasms; Hodgkin Diseas | 1972 |
Management of malignant lymphomas.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cel | 1973 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
Recently recognized complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Death, Sudden; Drug Therapy, Combination; | 1974 |
Drugs 5 years later: procarbazine.
Topics: Animals; Bone Neoplasms; Carcinogens; Carcinoma; Drug Evaluation; Hodgkin Disease; Humans; Lung Neop | 1974 |
54 trials available for procarbazine and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2011 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cispla | 2002 |
Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Europe; Female; Follow-Up S | 2005 |
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 2006 |
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1994 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomark | 1994 |
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1994 |
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 1994 |
Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1994 |
Combination chemotherapy with COP-BLAM III for intermediate and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1994 |
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1994 |
The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; | 1994 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
[The effects of COP-BLAM regimen with G-CSF for intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
[Usefulness of COP-BLAM therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 1995 |
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infec | 1993 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 1995 |
Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow | 1996 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; C | 1996 |
Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 1996 |
Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
[Usefulness of THP-COPBLM therapy in elderly patients with non-Hodgkin's lymphoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 1997 |
Multiple statistics for multiple events, with application to repeated infections in the growth factor studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Thera | 1997 |
Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, procarbazine (COP-BLAM) therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1998 |
Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen | 1998 |
[Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Child; Cyclo | 1997 |
[Combined modality therapy for malignant lymphoma of the primary central nervous system: a preliminary report of a new chemotherapeutic regimen with "PEACE"].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms | 1999 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2000 |
Treatment for primary CNS lymphoma: the next step.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2000 |
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.
Topics: Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration | 1977 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Topics: Adult; Aged; Blood Platelets; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Eto | 1991 |
ProMACE-C-MOPP in aggressive non-Hodgkin's lymphoma. Long-term results in 45 patients treated in a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1991 |
[Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; | 1987 |
Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical | 1987 |
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1988 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials | 1989 |
A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1987 |
Combination chemotherapy of lymphomas other than Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination | 1974 |
143 other studies available for procarbazine and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
[Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central N | 2022 |
Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Huma | 2023 |
Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Doxorubicin; Lymphoma; | 2023 |
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Disea | 2019 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case-Control Studies; Combined Mod | 2014 |
A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
Topics: Administration, Oral; Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemoth | 2009 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2012 |
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cy | 2012 |
NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Follic | 1965 |
[RESULTS OF CLINICAL TESTS OF A NEW CYTOSTATIC SUBSTANCE FROM THE METHYLHYDRAZINE SERIES (NATULAN)].
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Humans; Hydrazines; Leukemia; Leukemia, Lympho | 1965 |
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
[A case of secondary non-Hodgkin's lymphoma of the colon after the treatment for Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2005 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca | 2006 |
Procarbazine for non-Hodgkin's lymphoma.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Ho | 2006 |
Something old, something new....
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemc | 2006 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
[Lymphomas. Treatment of malignant lymphomas. Current observations and future prospects].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1982 |
Composite lymphoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Lymph Nodes; Lymphoma | 1984 |
Reversal of red cell aplasia and marrow fibrosis in non-Hodgkin's lymphoma.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; L | 1983 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
[VEPA and ML-Y1 regimen for elderly non-Hodgkin's lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 1994 |
[Type III procollagen N-terminal peptide and type IV collagen-7S level in the serum and BALF of patients with non-Hodgkin's lymphoma before and after chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchoalveolar | 1994 |
[Evaluation of pulmonary function and bronchoalveolar lavage fluid in elderly non-Hodgkin's lymphoma before and after COP-BLAM III therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchoalveolar Lavage Fluid; Cyclo | 1994 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dexametha | 1993 |
[Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplat | 1993 |
[COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Myelodysplastic syndrome after autologous transplant for lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Dis | 1994 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo | 1994 |
Relapsing chickenpox in a young man with non-Hodgkin's lymphoma.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Chickenpox; Cyclophosphamide; Doxo | 1994 |
Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1994 |
Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.
Topics: Animals; Dacarbazine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Guanine; Hodgkin | 1993 |
Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Flow Cyt | 1993 |
[Dysfunction of the blood-brain barrier in patients with acute leukemias or lymphomas of high grade malignancy].
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood- | 1995 |
[Non-Hodgkin's lymphoma in a patient after many years of remission of Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Lymphoma, No | 1995 |
[Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1996 |
[Assessment of cardiac toxicity by 123I-MIBG myocardial SPECT in elderly non-Hodgkin lymphoma patients treated with COP-BLAM and G-CSF].
Topics: 3-Iodobenzylguanidine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophospha | 1995 |
Therapy-related leukemia with a novel 21q22 rearrangement.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; | 1996 |
Chemotherapy-induced non-Hodgkin's lymphoma in a patient with Hodgkin's disease--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Cyclophosphamide; D | 1996 |
Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Burki | 1997 |
Five-year follow-up of saliva in patients treated for lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Amylases; Analysis of Variance; Antineoplastic Combined Ch | 1997 |
[Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Child; Child, P | 1996 |
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubi | 1996 |
THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
[Long term results of treatment of highly-malignant non-Hodgkin lymphoma in the elderly (70 years and older)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carmustine; Centra | 1998 |
Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined | 1998 |
Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1998 |
The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combine | 1999 |
Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diabetes Insipidus; Dox | 1999 |
Adult head and neck lymphomas in Papua New Guinea: a retrospective study of 70 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modali | 1999 |
Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1999 |
[Multivariate analysis on prognostic factors of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Do | 1997 |
Follow-up of sperm concentration and motility in patients with lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cryopreservation; Daca | 2000 |
Interferon does not prolong progression-free survival after ProMACE-MOPP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 2000 |
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2001 |
Primary pelvic non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 2001 |
Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2001 |
Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Behavior; Bleomyci | 2001 |
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV.
Topics: Adult; Antineoplastic Agents; Azirines; Bleomycin; Cyclophosphamide; Daunorubicin; Etoposide; Female | 1975 |
Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
Topics: Adult; Bleomycin; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Resistance; Drug Therapy, Com | 1977 |
Procarbazine-prochlorperazine interaction: an underreported phenomenon.
Topics: Adult; Basal Ganglia Diseases; Drug Interactions; Humans; Lymphoma, Non-Hodgkin; Male; Procarbazine; | 1978 |
Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential.
Topics: Aged; Ciliary Body; Cyclophosphamide; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Hu | 1977 |
Histiocytic lymphoma of B cell origin.
Topics: B-Lymphocytes; Cell Membrane; Humans; Immunoglobulins; Lymphoma, Large B-Cell, Diffuse; Lymphoma, No | 1977 |
[Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)].
Topics: Adult; Cyclophosphamide; Female; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Dif | 1977 |
[Therapy of non-Hodgkin lymphomas with COP and COPP regimens (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1977 |
[Reticulum cell sarcoma of the pelvis. Diagnostic and therapeutic problems].
Topics: Angiography; Cyclophosphamide; Hip Joint; Humans; Joint Prosthesis; Lymphoma, Non-Hodgkin; Male; Mid | 1978 |
Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug The | 1978 |
[Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphom | 1976 |
[Combination chemotherapy with vincristine, cyclophosphamide, procarbazine and prednisolone in advanced reticulum cell sarcoma (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Mal | 1976 |
A comparison of cyclophosphamide, vincristine, and prednisone (COP) with nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) in the treatment of nodular, poorly differentiated, lymphocytic lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; M | 1976 |
Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.
Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymph Nodes | 1975 |
Trichlortriethylamine (TS-160 Spofa) in combination chemotherapy of malignant lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Lymp | 1975 |
Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Femal | 1975 |
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1975 |
The influence of chemotherapy on the management of non-Hodgkin's lymphomata at the Princess Margaret Hospital. A comparison of the results from 1962-64 with 1967-69.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgki | 1975 |
Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1992 |
Primary central nervous system lymphoma: a role for adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1992 |
Left main coronary stenosis by a mediastinal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coronary Disease; Cyclophosphamide; Humans; Lymphoma | 1992 |
Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cells, Cultured; Chromosome Aberrations | 1992 |
Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; | 1990 |
Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1990 |
[The COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 1990 |
Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Behavior; Bleomyci | 1991 |
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antithrombin I | 1991 |
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1991 |
[A comparative study of CHOP therapy and COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
[The COP-BLAM III therapy of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1991 |
[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
[Hodgkin's disease associated with LDH-M subunit deficiency].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Isoenzymes; L-Lactate Dehy | 1991 |
Risk factors in intermediate and high-grade non-Hodgkin's lymphomas of adults: a need for a new staging system.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1991 |
Methyl transferase activity in secondary leukemia.
Topics: Acute Disease; B-Lymphocytes; Cell Line; Cell Transformation, Viral; DNA Repair; Herpesvirus 4, Huma | 1990 |
ECAPP chemotherapy for lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fema | 1990 |
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Et | 1990 |
Adjuvant chemotherapy for primary lymphoma of the central nervous system.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Dise | 1990 |
Non-Hodgkin's lymphoma. A four-drug regimen suitable for elderly patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Evaluation; Female; Humans; | 1990 |
Non-Hodgkin lymphoma: a rare primary vulvar localization.
Topics: Brain Neoplasms; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Pred | 1990 |
Advances in chemotherapy for large cell lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1987 |
Failure of conventional chemotherapy in aggressive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1987 |
Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1988 |
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease | 1988 |
The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
Non-Hodgkin's lymphoma in the elderly: a retrospective evaluation of toxicity related to aggressive vs. conservative treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1988 |
The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1988 |
Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
[Indirect endolymphatic chemotherapy of patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hodgkin Disease; Humans; Injection | 1989 |
[Studies of patients with non-Hodgkin's lymphoma unresponsive to C-MOPP].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance; Fema | 1988 |
The effects of four drug regimens on sister chromatid exchange frequency in patients with lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA Damage; Doxorubicin; Hodgkin D | 1988 |
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexametha | 1988 |
[Second tumors in patients treated for Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1988 |
A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1988 |
[Treatment of malignant lymphoma: 12 years' experience with 109 patients. 2). Treatment of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1987 |
Epirubicin in combination chemotherapy in the treatment of advanced stage non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclophosphamide; Doxorubic | 1987 |
[C-MOPP therapy in advanced diffuse lymphoma, large cell type (LSG)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymph | 1987 |
[Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 1986 |
[A preliminary study of chemo-interferon therapy in malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1987 |
Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Treatment of the lymphomas.
Topics: Bleomycin; Burkitt Lymphoma; Drug Synergism; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Ce | 1972 |
[Results of polychemotherapy in neoplasms of the lymphoreticular system].
Topics: Antineoplastic Agents; Cyclophosphamide; Hodgkin Disease; Humans; Infections; Leukopenia; Long-Term | 1973 |
Lymphosarcomatous arthropathy.
Topics: Arthritis; Biopsy; Cyclophosphamide; Female; Foot; Hand; Hematocrit; Humans; Lymphoma, Non-Hodgkin; | 1974 |
Conversion of Hodgkin's disease to lymphoblastic lymphosarcoma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Female; Hodgkin Disease; Humans; Liver; Lymph Node Excision; Ly | 1974 |
Temporary resolution of geographic tongue with cytotoxic therapy.
Topics: Child; Drug Therapy, Combination; Glossitis, Benign Migratory; Humans; Lymphoma, Non-Hodgkin; Male; | 1974 |
[Hodgkin's disease and other malignant lymphomas].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednison | 1972 |
Management of patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Lymphography; Ly | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Comment: the non-Hodgkin's lymphomas.
Topics: Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Large B-C | 1973 |
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy; Burkitt Lymphoma; Cyclophosphamide; Germ Cells; Ho | 1973 |
Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Injectio | 1973 |
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
[Hypoglycemia during lymphosarcoma and reticulosarcoma].
Topics: Adult; Alcoholism; Ascites; Biopsy; Coma; Cyclophosphamide; Edema; Humans; Hypoglycemia; Lymph Nodes | 1974 |
Alveolitis during procarbazine, vincristine and cyclophosphamide therapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Male; M | 1972 |
Status and perspectives in chemotherapy of Hodgkin's disease.
Topics: Animals; Antineoplastic Agents; Benzoates; Breast Neoplasms; Burkitt Lymphoma; Cyclophosphamide; Cyt | 1973 |
Chemotherapy of the lymphomas.
Topics: Adult; Burkitt Lymphoma; Child; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1974 |
Combined chemotherapy and radiotherapy for advanced Hodgkin's disease and reticulum cell sarcoma: a preliminary report.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lympho | 1971 |
Cyclic chemotherapy in lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Cyclophosphamide; Evaluation Studies as Topic; Female | 1971 |
Current concepts in the management of lymphoma.
Topics: Adolescent; Adult; Age Factors; Drug Synergism; Hepatomegaly; Hodgkin Disease; Humans; Immunologic D | 1971 |
Combination chemotherapy of advanced lymphomas.
Topics: Adult; Age Factors; Benzoates; Blood Cell Count; Blood Platelets; Cyclophosphamide; Drug Combination | 1972 |